Improving Intranasal Treatments with Dr. Ferrer BioPharma at CPHI Barcelona
November 3rd 2023Pharmaceutical Technology Europe® spoke with Gustavo Ferrer from Dr. Ferrer BioPharma, a US company focused on innovative intranasal medications, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.
Converting to Continuous Manufacturing with CONTINUUS Pharmaceuticals at CPHI Barcelona
November 3rd 2023Pharmaceutical Technology Europe® spoke with Leonardo Vincenzi from CONTINUUS Pharmaceuticals, a US company that specializes in process development, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.
Addressing the Analytical Challenge of Meeting Quick Turnaround Times (AAPS PharmSci 360)
November 2nd 2023Hollie Barton, senior director, Chromatographic Services, for the PPD clinical research business of Thermo Fisher Scientific, discusses ways that labs are addressing the pressure of rapid analytical turnaround times.
Making Visual Inspection Accessible with Luo Automation at CPHI Barcelona
November 2nd 2023Pharmaceutical Technology Europe® spoke with Joren van der Horst from Luo Automation, a Dutch company focused on automated visual inspection solutions, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.
Gently Encapsulating APIs with IamFluidics at CPHI Barcelona
November 1st 2023Pharmaceutical Technology Europe® spoke with Dr. Tom Kamperman from IamFluidics, a Dutch high-tech company that develops customized microencapsulation solutions, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.
Crucial Points from a Manufacturing Perspective (PDA/FDA Joint Regulatory Conference 2023)
October 17th 2023Sander Van Gessel, MEng, Business Unit Director, DFE Pharma, discusses the important components of nitrosamine impurities from a manufacturing point of view as a part of his session, "Reducing Nitrosamines Without the Use of Scavengers: The Critical Role of Excipients - An Excipient Manufacturer's View."
The Recent Discoveries of Nitrosamine Impurities (PDA/FDA Joint Regulatory Conference 2023)
October 16th 2023Sander Van Gessel, MEng, Business Unit Director, DFE Pharma, discusses the recent findings of nitrosamine impurities in human drugs as a part of his session, "Reducing Nitrosamines Without the Use of Scavengers: The Critical Role of Excipients - An Excipient Manufacturer's View."
The Challenges of the Journey from Clinical to Commercial Cell Therapies
October 12th 2023Humberto Vega, PhD, Executive Director, Bristol Myers Squibb, discusses the journey from clinical to commercial cell therapies as a part of his session, "Successfully Navigating Global Cell Therapy Requirements."